INSM

Insmed is expected to report a quarterly loss of $0.33 per share with revenues of $501.26 million when it releases Q3 2026 results on October 29. While revenues are projected to surge 252.2% year-over-year, the company's Earnings ESP of -3.48% combined with a Zacks Rank #3 makes it difficult to predict an earnings beat. The stock has beaten consensus estimates in 2 of the last 4 quarters.

Insmed's stock fell nearly 7% following the announcement that CFO Sara Bonstein will step down effective October 30 after nearly seven years in the role. Despite the leadership transition, the company reaffirmed its 2026 revenue guidance, expecting Brinsupri revenues of $1.25-$1.40 billion and Arikayce sales of $450-$470 million. The decline reflects investor uncertainty about the unexpected departure of a key executive during a critical growth phase.

A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals.